Related Experiment Videos
Cardioversion of atrial arrhythmias: audit of anticoagulation management
1Department of Cardiology, Hillingdon Hospital, Middlesex.
Insights
Anticoagulation therapy for cardioversion of atrial fibrillation and atrial flutter is often inadequate. This audit revealed inconsistent pre- and post-procedure anticoagulation, highlighting the need for a formal policy to prevent thromboembolic complications.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardioversion for atrial arrhythmias carries a risk of thromboembolic complications.
- Guidelines recommend specific anticoagulation protocols before and after cardioversion.
Purpose of the Study:
- To audit the consistency and adequacy of anticoagulation practices for patients undergoing cardioversion.
- To identify deviations from recommended anticoagulation guidelines.
Main Methods:
- Retrospective audit of 56 patients (36 acute, 20 elective) undergoing cardioversion for atrial fibrillation or atrial flutter.
- Review of anticoagulation records (heparin, warfarin) and use of transoesophageal echocardiography.
Main Results:
- Anticoagulation was inconsistent and often inadequate in both acute and elective cardioversion settings.
- Many patients did not receive recommended pre- or post-procedure anticoagulation with warfarin.
- Transoesophageal echocardiography was infrequently used to rule out thrombi.
Conclusions:
- Current anticoagulation practices for cardioversion are frequently insufficient to mitigate thromboembolic risk.
- A formal anticoagulation policy for cardioversion is necessary to ensure adherence to guidelines.
- Improved adherence to anticoagulation protocols is crucial for patient safety.
Abstract:
Patients undergoing cardioversion for chronic atrial fibrillation should receive anticoagulation for three weeks before and four weeks after the procedure. Patients with atrial flutter and acute atrial fibrillation are also at risk of thromboembolic complications, so they too should be anticoagulated for cardioversion. Of the 36 acutely admitted patients who were cardioverted, 18 were in atrial fibrillation and 18 in atrial flutter. All except three of those in fibrillation were anticoagulated with heparin before cardioversion, but only seven received warfarin after cardioversion. Of those in flutter, 10 received heparin and eight received no anticoagulation before cardioversion. One patient underwent transoesophageal echocardiography before cardioversion to exclude atrial thrombi. Only two patients received warfarin for a month after cardioversion. Of the 20 elective cardioversions, 10 were in atrial fibrillation and 10 in atrial flutter. Five of those in fibrillation had received at least three weeks' treatment with warfarin before cardioversion and two underwent transoesophageal echocardiography; the other three received either up to two hours of heparin or no anticoagulation before cardioversion. Only five patients received warfarin for a month after cardioversion. Nine of those in flutter received a few hours of heparin before cardioversion and one was not anticoagulated; none underwent transoesophageal echocardiography or received warfarin after cardioversion. The results of this audit demonstrate that anticoagulation for atrial arrhythmias was inconsistent and often inadequate. A formal anticoagulation policy for cardioversion has now been adopted.